Women with gestational diabetes, controlled with diet, were randomized to receive placebo or glyburide. Primary outcome was a decrease in birth weight of 200g. Secondary maternal outcomes included need for insulin and associated adverse outcomes such as chorioamnionitis, pregnancy-induced hypertension, need for operative delivery, shoulder dystocia and third and fourth degree perineal lacerations. Secondary newborn outcomes included small for gestational age (SGA) and large for gestational age (LGA), as well as birth trauma, hypoglycemia, umbilical artery pH of less than or equal to 7 and high bilirubin.
Diet control for the treatment of mild gestational diabetes is known to reduce birthweight and is the mainstay of therapy. The authors, in a well-designed randomized controlled study, set out to determine if adding glyburide would further decrease birthweight which is associated with adverse outcomes such as birth trauma, shoulder dystocia and neonatal hypoglycemia (Obstet Gynecol 2015). Women with mild gestational diabetes (fasting glucose below 105/mg/dL with at least 2 elevated values on the 3 hour glucose tolerance test) using the National Diabetes Data Group criteria were randomized into glyburide and placebo groups. Even though this study demonstrated that glycemic profiles were significantly improved with the addition of glyburide, there was no additional benefit with the addition of glyburide to diet therapy.
Glyburide in Women With Mild Gestational Diabetes: A Randomized Controlled Trial
Please log in to ObGFirst to access the 2T US Atlas
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
